Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis
Name:
37334528.pdf
Size:
877.1Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
Department of Oncology-Pathology, Karolinska Institutet/Thoracic Oncology Center, Karolinska University Hospital, Stockholm, SwedenIssue Date
2023
Metadata
Show full item recordAbstract
The presence of brain metastases (BM) is a negative prognostic factor for patients with advanced nonsmall cell lung cancer (NSCLC). Their incidence seems to be higher in patients with oncogene-driven tumours, especially those with EGFR-mutated or ALK-rearranged tumours. Although targeted treatments demonstrate significant efficacy regarding BM, they only apply to a minority of NSCLC patients. On the other hand, systemic therapies for nononcogenic-driven NSCLC with BM have shown limited clinical benefit. In recent years, immunotherapy alone or combined with chemotherapy has been adopted as a new standard of care in first-line therapy. This approach seems to be beneficial to patients with BM in terms of efficacy and toxicity. Combined immune checkpoint inhibition as well as the combination of immunotherapy and radiation therapy show promising results with significant, but overall acceptable toxicity. A pragmatic approach of allowing enrolment of patients with untreated or symptomatic BM in randomised trials evaluating immune checkpoint inhibitors strategies, possibly coupled with central nervous system-related endpoints may be needed to generate data to refine treatment for this patient population.Citation
Tsakonas G, Ekman S, Koulouris A, Adderley H, Ackermann CJ, Califano R. Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis. Int J Cancer. 2023 Jun 19. PubMed PMID: 37334528. Epub 2023/06/19. eng.Journal
International Journal of CancerDOI
10.1002/ijc.34628PubMed ID
37334528Additional Links
https://dx.doi.org/10.1002/ijc.34628Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1002/ijc.34628
Scopus Count
Collections
Related articles
- The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases.
- Authors: Wu X, Stabile LP, Burns TF
- Issue date: 2024 Sep
- Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
- Authors: Li W, Jiang J, Huang L, Long F
- Issue date: 2022 Jan
- Systemic Therapy for Lung Cancer Brain Metastases.
- Authors: Pellerino A, Bruno F, Rudà R, Soffietti R
- Issue date: 2021 Oct 25
- Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
- Authors: Zhang B, Zeng J, Zhang H, Zhu S, Wang H, He J, Yang L, Zhou N, Zu L, Xu X, Song Z, Xu S
- Issue date: 2022
- Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
- Authors: Vilariño N, Bruna J, Bosch-Barrera J, Valiente M, Nadal E
- Issue date: 2020 Sep